AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17030764 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 30
Study 17030764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12757076 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 drain inserted at the axilla area (Group I)
Number of subjects: 60
Study 12757076 — intervention group
Group type: COMPARATOR
Intervention: 2 conventional drains inserted into the pectoral area and axilla area (Group II)
Number of subjects: 60
Study 9989194 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches (21 mg/day)
Number of subjects: 522
Study 9989194 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patches (14 mg/day)
Number of subjects: 522
Study 9989194 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 522
Study 8524578 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine HCl 0.5%
Number of subjects: 12
Study 8524578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine HCl 1%
Number of subjects: 12
Study 8524578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine HCl 2%
Number of subjects: 12
Study 8524578 — intervention group
Group type: COMPARATOR
Intervention: Control (no miotic employed)
Number of subjects: 12
Study 2152664 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-supplemented milk (15 mg elementary iron as ferrous sulphate and 100 mg ascorbic acid per 100 g powder)
Number of subjects: 86
Study 2152664 — intervention group
Group type: COMPARATOR
Intervention: Control group (same milk with no supplement)
Number of subjects: 86
Study 575490 — intervention group
Group type: EXPERIMENTAL
Intervention: 1020 mg creatinol O-phosphate (group A)
Number of subjects: 4
Study 575490 — intervention group
Group type: EXPERIMENTAL
Intervention: 2040 mg creatinol O-phosphate (group B)
Number of subjects: 4
Study 575490 — intervention group
Group type: EXPERIMENTAL
Intervention: 3060 mg creatinol O-phosphate (group C)
Number of subjects: 4
Study 575490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group D)
Number of subjects: 4
Study 30799646 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy (TT)
Number of subjects: 440
Study 30799646 — intervention group
Group type: COMPARATOR
Intervention: Immuno-oncology (IO)
Number of subjects: 440
Study 28183326 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV3) administered at day 1 and day 180
Number of subjects: 200
Study 28183326 — intervention group
Group type: COMPARATOR
Intervention: Tetanus‐diphtheria‐pertussis vaccine administered at day 180
Number of subjects: 200
Study 26615504 — intervention group
Group type: EXPERIMENTAL
Intervention: Crestal implants (group A)
Number of subjects: 23
Study 26615504 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcrestal implants (group B)
Number of subjects: 23
Study 26615504 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 23
Study 24472518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600mg/day)
Number of subjects: 0
Study 24472518 — intervention group
Group type: EXPERIMENTAL
Intervention: NPSI questionnaire
Number of subjects: 0
Study 24472518 — intervention group
Group type: EXPERIMENTAL
Intervention: QST
Number of subjects: 0
Study 24472518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical cluster analysis
Number of subjects: 0
Study 22038939 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 20
Study 22038939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20658249 — intervention group
Group type: COMPARATOR
Intervention: Heat stress alone
Number of subjects: 8
Study 20658249 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 8
Study 20658249 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined heat stress and exercise
Number of subjects: 8
Study 17670997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 208
Study 16299118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal NIV
Number of subjects: 48
Study 16299118 — intervention group
Group type: COMPARATOR
Intervention: Control group without ventilatory support
Number of subjects: 48
Study 11750964 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone prophylaxis after amniocentesis
Number of subjects: 0
Study 11750964 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study 9865559 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual sphincterotomy (group I, n = 30)
Number of subjects: 60
Study 9865559 — intervention group
Group type: COMPARATOR
Intervention: Pancreatic sphincterotomy alone (group II, n = 30)
Number of subjects: 60
Study 7882873 — intervention group
Group type: EXPERIMENTAL
Intervention: Passages (modified therapeutic community methods)
Number of subjects: 327
Study 7882873 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone maintenance therapy (comparison group)
Number of subjects: 327
Study 31797190 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 90
Study 30132224 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of terlipressin (Group A)
Number of subjects: 86
Study 30132224 — intervention group
Group type: COMPARATOR
Intervention: Intravenous boluses of terlipressin (Group B)
Number of subjects: 86
Study 30132224 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of terlipressin
Number of subjects: 86
Study 30132224 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD-Na score
Number of subjects: 86
Study 28791734 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute alcohol dose at 0.4 or 0.6 g/kg
Number of subjects: 96
Study 28791734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 28791734 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinkers
Number of subjects: 96
Study 28791734 — intervention group
Group type: EXPERIMENTAL
Intervention: Light drinkers
Number of subjects: 96
Study 28791734 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 96
Study 26271327 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) disclosure
Number of subjects: 220
Study 26271327 — intervention group
Group type: COMPARATOR
Intervention: Conventional risk score (CRS) disclosure
Number of subjects: 220
Study 26271327 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial measures
Number of subjects: 220
Study 24056196 — intervention group
Group type: EXPERIMENTAL
Intervention: PD patients OFF medication
Number of subjects: 21
Study 24056196 — intervention group
Group type: EXPERIMENTAL
Intervention: PD patients ON medication
Number of subjects: 21
Study 24056196 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 21
Study 21726949 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin stretching (SS)
Number of subjects: 0
Study 21726949 — intervention group
Group type: COMPARATOR
Intervention: Scar excision without additional techniques (SE)
Number of subjects: 0
Study 19800611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 20
Study 19800611 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 20
Study 17086500 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity-sensing chair with auditory feedback
Number of subjects: 20
Study 17086500 — intervention group
Group type: COMPARATOR
Intervention: Without auditory feedback device
Number of subjects: 20
Study 15623196 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0-cm wide cuff
Number of subjects: 17
Study 15623196 — intervention group
Group type: COMPARATOR
Intervention: 2.5-cm wide cuff
Number of subjects: 17
Study 15623196 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 17
Study 15623196 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 17
Study 11239189 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapy (specific details not provided)
Number of subjects: 448
Study 8976244 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐reinforced polyglycolic acid spiral stent
Number of subjects: 72
Study 8976244 — intervention group
Group type: COMPARATOR
Intervention: Suprapubic catheter
Number of subjects: 72
Study 8976244 — intervention group
Group type: COMPARATOR
Intervention: Indwelling catheter
Number of subjects: 72
Study 8976244 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 72
Study 7965649 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (specific agents not detailed)
Number of subjects: 0
Study 7965649 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 0
Study 3119687 — intervention group
Group type: EXPERIMENTAL
Intervention: Renografin‐76
Number of subjects: 816
Study 3119687 — intervention group
Group type: COMPARATOR
Intervention: Angiovist‐370
Number of subjects: 816
Study 29324972 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 413
Study 29324972 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 413
Study 27529771 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.9-g/d n-3 PUFA treatment
Number of subjects: 92
Study 27529771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 24632963 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 200
Study 24632963 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 200
Study 23338733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine injection
Number of subjects: 42
Study 23338733 — intervention group
Group type: COMPARATOR
Intervention: Control group (no analgesia)
Number of subjects: 42
Study 21126390 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (1 mg/kg per day) for 7 days
Number of subjects: 68
Study 21126390 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 68
Study 18791910 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic resection
Number of subjects: 25
Study 18791910 — intervention group
Group type: COMPARATOR
Intervention: Open excision
Number of subjects: 25
Study 15905731 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretrovirals (ARVs)
Number of subjects: 8451
Study 15905731 — intervention group
Group type: EXPERIMENTAL
Intervention: Single, dual, and triple nucleoside reverse transcriptase inhibitors (NRTIs)
Number of subjects: 8451
Study 15905731 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 8451
Study 15905731 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) with hydroxyurea (HU)
Number of subjects: 8451
Study 15905731 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) with stavudine (d4T)
Number of subjects: 8451
Study 15905731 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (IDV)/didanosine (ddI)/stavudine (d4T) with or without hydroxyurea (HU)
Number of subjects: 8451
Study 12894613 — intervention group
Group type: EXPERIMENTAL
Intervention: Consenting group (CG)
Number of subjects: 0
Study 12894613 — intervention group
Group type: COMPARATOR
Intervention: Nonconsenting group (NG)
Number of subjects: 0
Study 10589441 — intervention group
Group type: EXPERIMENTAL
Intervention: Maté (Ilex paraguariensis) extract
Number of subjects: 0
Study 10589441 — intervention group
Group type: COMPARATOR
Intervention: Other commercially available plant preparations
Number of subjects: 0
Study 8947991 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 4
Study 8947991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 4
Study 1931471 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO1567 (100 mg daily)
Number of subjects: 0
Study 1931471 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO1567 (200 mg daily)
Number of subjects: 0
Study 6809421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical levonorgestrel‐releasing mini‐T device
Number of subjects: 100
Study 6809421 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine levonorgestrel device
Number of subjects: 100
Study 6809421 — intervention group
Group type: COMPARATOR
Intervention: Copper‐T‐200 (Cu‐T‐200)
Number of subjects: 100
Study 6809421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both levonorgestrel devices
Number of subjects: 100
Study 31081693 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1RA (specific drugs include liraglutide, exenatide, and lixisenatide)
Number of subjects: 4242
Study 31081693 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 4242
Study 31081693 — intervention group
Group type: COMPARATOR
Intervention: Exenatide
Number of subjects: 4242
Study 31081693 — intervention group
Group type: COMPARATOR
Intervention: Lixisenatide
Number of subjects: 4242
Study 28278333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg daily for 1 year)
Number of subjects: 1069
Study 28278333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (800 mg daily for 1 year)
Number of subjects: 1069
Study 28278333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1069
Study 26245724 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music (water and wave sounds)
Number of subjects: 37
Study 26245724 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 37
Study 24461877 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 g amino acids/(kg·d) plus 2-3 g lipid/(kg·d)
Number of subjects: 28
Study 24461877 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 g amino acids/(kg·d) plus 2-3 g lipid/(kg·d)
Number of subjects: 28
Study 24461877 — intervention group
Group type: COMPARATOR
Intervention: 2.4 g amino acids/(kg·d) (control group)
Number of subjects: 28
Study 24461877 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing energy intake from 40 to 60 kcal/(kg·d)
Number of subjects: 28
Study 22542332 — intervention group
Group type: COMPARATOR
Intervention: Continuous Wave (CW) CO(2) laser (5 W)
Number of subjects: 60
Study 22542332 — intervention group
Group type: EXPERIMENTAL
Intervention: Char-Free (CF) CO(2) laser (140 Hz, 400 μs, 33 mJ)
Number of subjects: 60
Study 19593180 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (VEN) administered at daily dosages ranging from 75 to 150 mg.
Number of subjects: 28
Study 17478166 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D echocardiography using > or = 6 component 2D image planes
Number of subjects: 25
Study 17478166 — intervention group
Group type: COMPARATOR
Intervention: Biplane 2D echocardiography
Number of subjects: 25
Study 17478166 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D echocardiography using 4, 6, 8, 10, and 20 component 2D planes
Number of subjects: 25
Study 17478166 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D echocardiography
Number of subjects: 25
Study 15516884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.7 mg/kg)
Number of subjects: 40
Study 15516884 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (15 mg/kg)
Number of subjects: 40
Study 11505244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Model of Everyday Memory intervention
Number of subjects: 0
Study 11505244 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9760804 — intervention group
Group type: EXPERIMENTAL
Intervention: LATP test with ECG, ECHO, and SPECT
Number of subjects: 55
Study 9760804 — intervention group
Group type: EXPERIMENTAL
Intervention: LATP test with SPECT
Number of subjects: 55
Study 9760804 — intervention group
Group type: EXPERIMENTAL
Intervention: LATP test with ECHO
Number of subjects: 55
Study 9760804 — intervention group
Group type: COMPARATOR
Intervention: LATP test with ExT
Number of subjects: 55
Study 8155446 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with low-dose (10 micrograms kg‐1) fentanyl
Number of subjects: 51
Study 8155446 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (high-dose 50 micrograms kg‐1) with midazolam
Number of subjects: 51
Study 3412292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal pine extract (0.15 cc by metered dose spray, starting at 1/100,000 w/v, followed by 1/10,000, 1/1000 and 1/100 at 20 minute intervals)
Number of subjects: 100
Study 3412292 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive skin test (ST) to pine pollen extract
Number of subjects: 100
Study 3412292 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-tree mixture
Number of subjects: 100
Study 3412292 — intervention group
Group type: COMPARATOR
Intervention: Skin testing with pine pollen extract, 8-tree mixture, histamine and negative control
Number of subjects: 100
Study 31822016 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically Healthy Overweight/Obese Children (MHO)
Number of subjects: 188
Study 31822016 — intervention group
Group type: COMPARATOR
Intervention: Moderate-to-Vigorous Physical Activity (MVPA)
Number of subjects: 188
Study 31822016 — intervention group
Group type: COMPARATOR
Intervention: Cardiorespiratory Fitness (CRF)
Number of subjects: 188
Study 31064896 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous Ready‐to‐use Therapeutic Food (Medical Nutrition Therapy)
Number of subjects: 1105
Study 31064896 — intervention group
Group type: COMPARATOR
Intervention: Standard Nutrition Therapy
Number of subjects: 1105
Study 28433887 — intervention group
Group type: EXPERIMENTAL
Intervention: Clay Art Therapy (CAT)
Number of subjects: 106
Study 28433887 — intervention group
Group type: COMPARATOR
Intervention: Visual Art (VA)
Number of subjects: 106
Study 26385052 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (6.4 g/day for 18 months)
Number of subjects: 0
Study 26385052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23622086 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admissions from 1988 to 2012
Number of subjects: 482601
Study 23622086 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic obstructive pulmonary disease, seizures, surgery for aortic dissection and subarachnoid hemorrhage
Number of subjects: 482601
Study 23622086 — intervention group
Group type: EXPERIMENTAL
Intervention: Six diagnoses (not specified)
Number of subjects: 482601
Study 23622086 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven diagnoses (not specified)
Number of subjects: 482601
Study 23622086 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admissions from 2001 to 2012
Number of subjects: 482601
Study 21559279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administration within three hours of injury
Number of subjects: 1000
Study 21559279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of administering TXA
Number of subjects: 1000
Study 21559279 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cost of giving TXA versus not giving TXA
Number of subjects: 1000
Study 21559279 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated incremental cost per LY gained of administering TXA
Number of subjects: 1000
Study 19327910 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) to the head and neck
Number of subjects: 15
Study 17573455 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietics (for anemia)
Number of subjects: 0
Study 17573455 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study 17573455 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychostimulants
Number of subjects: 0
Study 17573455 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine
Number of subjects: 0
Study 17573455 — intervention group
Group type: EXPERIMENTAL
Intervention: modafinil
Number of subjects: 0
Study 17573455 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion
Number of subjects: 0
Study 17573455 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine
Number of subjects: 0
Study 15010082 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Bedrest
Number of subjects: 82
Study 15010082 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone-T3
Number of subjects: 82
Study 15010082 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate-T3
Number of subjects: 82
Study 15010082 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 plus bedrest
Number of subjects: 82
Study 11213869 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal plan permitting up to 10% of total energy as added sugars or sweets (S)
Number of subjects: 48
Study 11213869 — intervention group
Group type: COMPARATOR
Intervention: Conventional meal plan (no concentrated sweets) (C)
Number of subjects: 48
Study 9846910 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg at 8-h intervals for 5 days)
Number of subjects: 106
Study 9846910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 8635830 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ferrous sulphate (FeSO4) tablet per day for 15 weeks
Number of subjects: 81
Study 8635830 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO4 tablets along with 2,000,000 IU of vitamin A as single dose
Number of subjects: 81
Study 8635830 — intervention group
Group type: COMPARATOR
Intervention: No supplements (Control)
Number of subjects: 81
Study 2469747 — intervention group
Group type: EXPERIMENTAL
Intervention: organo-heparinoid cream (Hirudoid)
Number of subjects: 12
Study 2469747 — intervention group
Group type: COMPARATOR
Intervention: placebo cream
Number of subjects: 12
Study 908448 — intervention group
Group type: EXPERIMENTAL
Intervention: Tantalum clips
Number of subjects: 110
Study 908448 — intervention group
Group type: COMPARATOR
Intervention: Conventional vasectomy (control)
Number of subjects: 110
Study 908448 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Tantalum clips and Conventional vasectomy)
Number of subjects: 110
Study 908448 — intervention group
Group type: EXPERIMENTAL
Intervention: Recanalization methods after clip removal
Number of subjects: 110
Study 31535922 — intervention group
Group type: EXPERIMENTAL
Intervention: Great Village
Number of subjects: 142
Study 31535922 — intervention group
Group type: EXPERIMENTAL
Intervention: Great Village + exercise
Number of subjects: 142